NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $308.79 -7.48 (-2.37%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$308.07 -0.72 (-0.23%) As of 11/13/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ligand Pharmaceuticals Stock (NASDAQ:LGND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ligand Pharmaceuticals alerts:Sign Up Key Stats Today's Range$308.59▼$314.7950-Day Range$275.20▼$322.7552-Week Range$175.89▼$326.63Volume129,023 shsAverage Volume215,877 shsMarket Capitalization$6.18 billionP/E Ratio137.85Dividend YieldN/APrice Target$355.38Consensus RatingModerate Buy Company Overview Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas. Founded in 1987, the company serves markets through its partners, whose development and commercialization activities extend across the United States and internationally.AI Generated. May Contain Errors. Read More Ligand Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreLGND MarketRank™: 3.638506876225 of 5 starsLigand Pharmaceuticals scored higher than 73% of companies evaluated by MarketBeat, and ranked 241st out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingLigand Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialLigand Pharmaceuticals has a consensus price target of $355.38, representing about 15.1% upside from its current price of $308.79.Amount of Analyst CoverageLigand Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ligand Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth243.83% Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 243.83% in the coming year, from $2.35 to $8.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 137.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 137.85, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 5.52. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 6.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.05% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 10.53, which indicates bearish sentiment.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently decreased by 1.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.69 News SentimentLigand Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ligand Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest4 people have searched for LGND on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows3 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,585,447.00 in company stock.Percentage Held by Insiders5.60% of the stock of Ligand Pharmaceuticals is held by insiders.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LGND Stock News HeadlinesLigand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $350.00November 14 at 3:59 AM | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Director Jason Aryeh Sells 3,000 Shares of StockNovember 13 at 5:52 AM | insidertrades.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $402.00November 8, 2026 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Director Jason Aryeh Sells 282 Shares of Company StockNovember 7, 2026 | insidertrades.comHC Wainwright Has Negative Opinion of LGND FY2026 EarningsNovember 7, 2026 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares of StockNovember 5, 2026 | insidertrades.comLigand Pharmaceuticals (NASDAQ:LGND) Director Sells 700 Shares of Company StockNovember 4, 2026 | insidertrades.comSee More Headlines LGND Stock Analysis - Frequently Asked Questions How have LGND shares performed this year? Ligand Pharmaceuticals' stock was trading at $189.07 on January 1st, 2026. Since then, LGND shares have increased by 63.3% and is now trading at $308.79. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its earnings results on Thursday, October, 29th. The biotechnology company reported $2.67 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.34. Ligand Pharmaceuticals's revenue for the quarter was down 31.8% compared to the same quarter last year. Read the conference call transcript. Who are Ligand Pharmaceuticals' major shareholders? Top institutional shareholders of Ligand Pharmaceuticals include Congress Asset Management Co. (3.30%), Stephens Investment Management Group LLC (2.23%), GW&K Investment Management LLC (1.21%) and Russell Investments Group Ltd. (0.85%). Insiders that own company stock include Todd C Davis, Matthew E Korenberg, John W Kozarich, Stephen L Sabba, Andrew Reardon, Octavio Espinoza, John L Lamattina, Nancy Ryan Gray, Jason Haas and Martine Zimmermann. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Block (XYZ) and Palo Alto Networks (PANW). Company Calendar Last Earnings10/29/2026Today11/15/2026Investor Day 202612/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 LGND's financial health is in the Green zone, according to TradeSmith. LGND has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees47Year Founded1987Price Target and Rating Average Price Target for Ligand Pharmaceuticals$355.38 High Price Target$402.00 Low Price Target$326.00 Potential Upside/Downside+15.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$2.24 Trailing P/E Ratio137.85 Forward P/E Ratio38.22 P/E Growth5.52Net Income$124.45 million Net Margins20.27% Pretax Margin20.77% Return on Equity5.22% Return on Assets2.74% Debt Debt-to-Equity Ratio0.71 Current Ratio1.22 Quick Ratio1.19 Sales & Book Value Annual Sales$268.09 million Price / Sales23.04 Cash Flow$7.67 per share Price / Cash Flow40.28 Book Value$48.08 per share Price / Book6.42Miscellaneous Outstanding Shares20,000,000Free Float18,883,000Market Cap$6.18 billion OptionableOptionable Beta1.16 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:LGND) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredSHOCKING! Prediction caught on cameraNewly released footage shows James Altucher pulling a document out of a briefcase on camera. It is a document ...Paradigm Press | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
